Article
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Mar 2017
Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord J-P, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin M-P, Paoletti X, Servois V, Le Tourneau C
Abstract excerpt
Background: Several studies used the ratio of progression-free survival (PFS) on genotype-matched treatment to PFS on genotype-unmatched treatment to assess the efficacy of therapy guided by patients' tumor molecular profiling. We evaluated the PFS ratio from patients who cross-over in the SHIVA trial. Patients and methods: The primary end point of the SHIVA trial was to compare PFS on molecularly targeted agents...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.